Catalyst Wire Dossier Catalyst Wire Dossier

SERCA2a modulator (experimental)

SERCA2a modulator · Sardocor Corp.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for SERCA2a modulator (experimental), covering 2025-02-27 to 2025-02-27. Get the full timeline:

Most recent: Clinical Trial Update: Modulation of SERCA2a of Intra-Myocytic Calcium Trafficking in Cardiomyopathy Secondary to Duchenne Muscular Dystrophy [Phase 1]

See pricing